Pfizer says COVID-19 vaccine safe and effective for children as young as five
Pfizer Inc. PFE, -1.30% and German partner BioNTech SE BNTX, -3.61% on Monday announced positive results in a Phase 2/3 trial of their COVID-19 vaccine in children aged 5 to 11, and said the vaccine was safe, well tolerated and produced"robust" neutralizing antibody response. The companies said participants in the trial were given a two-dose regimen of 10 ug administered 21 days apart, a smaller dose than the 30 ug given to people aged 12 and older.
These are the first results from a pivotal trial of a COVID-19 vaccine in this age group." The companies are planning to submit the data to the Food and Drug Administration and the European Medicines Agency, as well as to other regulators around the world as soon as possible. Results from a trial involving children younger than 5 are expected"as soon as later this year," said the statement. "Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Long Covid Affecting One Third Of People After Covid-19 Coronavirus Infection, CDC MMWR Study FindsSymptom rates were higher among females, Black people, and those 40 years and older or with pre-existing conditions.
Consulte Mais informação »
Covid-19: NI records five Covid-linked deaths, 889 casesThe total number of deaths linked to coronavirus in NI since the start of the pandemic is 2,504
Consulte Mais informação »
Pfizer says COVID-19 vaccine safe, effective for kids ages 5 to 11Pfizer and BioNTech released data saying its vaccine is safe and effective for kids 5-11.
Consulte Mais informação »
Pfizer says COVID-19 vaccine works in kids ages 5 to 11Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon -- a key step toward beginning vaccinations for youngsters. The vaccine made by Pfizer and its German partner BioNTech already is available for anyone 12 and older.
Consulte Mais informação »
U.S. and EU struggle with the same question: How to maximize COVID-19 vaccinationsDespite apparently divergent strategies, officials in both the U.S. and the EU are struggling with the same question: how to boost vaccination rates to the max and end a pandemic that has repeatedly thwarted efforts to control it.
Consulte Mais informação »
COVID-19 testing costs for travel are outrageous, signal profiteeringOpinion | Private companies are exploiting international travelers with outrageous COVID-19 testing costs. By GabsP78.
Consulte Mais informação »